Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Clinical and experimental studies have shown that sodium glucose co-transporter 2 inhibitors (SGLT2i) contribute to the prevention of diabetic kidney disease progression. In order to clarify its pharmacological effects on the molecular mechanisms underlying the development of diabetic kidney disease, we administered different doses of the SGLT2i, ipragliflozin, to type 2 diabetic mice. A high-dose ipragliflozin treatment for 8 weeks lowered blood glucose levels and reduced urinary albumin excretion. High- and low-dose ipragliflozin both inhibited renal and glomerular hypertrophy, and reduced NADPH oxidase 4 expression and subsequent oxidative stress. Analysis of glomerular phenotypes using glomeruli isolation demonstrated that ipragliflozin preserved podocyte integrity and reduced oxidative stress. Regarding renal tissue hypoxia, a short-term ipragliflozin treatment improved oxygen tension in the kidney cortex, in which SGLT2 is predominantly expressed. We then administered ipragliflozin to type 1 diabetic mice and found that high- and low-dose ipragliflozin both reduced urinary albumin excretion. In conclusion, we confirmed dose-dependent differences in the effects of ipragliflozin on early diabetic nephropathy in vivo. Even low-dose ipragliflozin reduced renal cortical hypoxia and abnormal hemodynamics in early diabetic nephropathy. In addition to these effects, high-dose ipragliflozin exerted renoprotective effects by reducing oxidative stress in tubular epithelia and glomerular podocytes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Blood Pressure Lowering in Type 2 Diabetes: A Systematic Review and Meta-analysis
Emdin, C. A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., & Patel, A. (2015) · JAMA · doi:10.1001/jama.2014.18574 · Cited by 854
Kohan, D. E., Fioretto, P., Tang, W., & List, J. F. (2014) · Kidney International · doi:10.1038/ki.2013.356 · Cited by 652
Differentiated kidney epithelial cells repair injured proximal tubule
Kusaba, T., Lalli, M., Kramann, R., Kobayashi, A., & Humphreys, B. D. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310653110 · Cited by 476
Self-citationEmpagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U. C., & Woerle, H. J. (2015) · Diabetes Care · doi:10.2337/dc14-1096 · Cited by 468
Baker, W. L., Smyth, L. R., Riche, D. M., Bourret, E. M., Chamberlin, K. W., & White, W. B. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.01.007 · Cited by 452
Sedeek, M., Callera, G., Montezano, A., Gutsol, A., Heitz, F., Szyndralewiez, C., Page, P., Kennedy, C. R. J., Burns, K. D., Touyz, R. M., et al. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00028.2010 · Cited by 396
Vallon, V., Rose, M., Gerasimova, M., Satriano, J., Platt, K. A., Koepsell, H., Cunard, R., Sharma, K., Thomson, S. C., & Rieg, T. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00409.2012 · Cited by 370
Canagliflozin slows progression of renal function decline independently of glycemic effects
Heerspink, H. J. L., Desai, M., Jardine, M., Balis, D., Meininger, G., & Perkovic, V. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030278 · Cited by 361
Cited by
Tomita, I., Kume, S., Sugahara, S., Osawa, N., Yamahara, K., Yasuda-Yamahara, M., Takeda, N., Chin-Kanasaki, M., Kaneko, T., Mayoux, E., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.020 · Cited by 376
Yang, Z., Li, T., Xian, J., Chen, J., Huang, Y., Zhang, Q., Lin, X., Lu, H., & Lin, Y. (2022) · The FASEB Journal · doi:10.1096/fj.202200243r · Cited by 79
Kitada, M., Hirai, T., & Koya, D. (2020) · Diabetology International · doi:10.1007/s13340-020-00444-8 · Cited by 19
Metadata
- Authors
- Kamezaki, M., Kusaba, T., Komaki, K., Fushimura, Y., Watanabe, N., Ikeda, K., Kitani, T., Yamashita, N., Uehara, M., Kirita, Y., Shiotsu, Y., Sakai, R., Fukuda, T., Yamazaki, M., Fukui, M., Matoba, S., & Tamagaki, K.
- Venue
- Scientific Reports
- Published
- 2018-03-05
- Volume
- 8
- Issue
- 1
- Pages
- 4029-4029
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2796903473
- Cited by
- 73
- References
- 14
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice. https://app.cochat.ai/papers/10.1038/s41598-018-22229-5
- The paper
- Kamezaki, M., Kusaba, T., Komaki, K., Fushimura, Y., Watanabe, N., Ikeda, K., Kitani, T., Yamashita, N., Uehara, M., Kirita, Y., Shiotsu, Y., Sakai, R., Fukuda, T., Yamazaki, M., Fukui, M., Matoba, S., & Tamagaki, K. (2018). Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice. Scientific Reports. https://doi.org/10.1038/s41598-018-22229-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.